Form 4: Day One Biopharma GC Sells Shares for Tax

Day One Biopharmaceuticals General Counsel Adam Dubow sold 4,365 shares of common stock to cover tax liabilities from Restricted Stock Unit settlements.

Summary

• Adam Dubow, General Counsel and Secretary of Day One Biopharmaceuticals, Inc. (DAWN), acquired 12,087 shares of common stock on August 15, 2025, through the settlement of Restricted Stock Units (RSUs).
• Following the RSU settlements, Dubow sold 4,365 shares of common stock on August 18, 2025, at a weighted average price of $6.7671 per share.
• The sale was explicitly for the sole purpose of covering tax liabilities associated with the RSU settlements.
• The shares were sold as part of block trades at prices ranging from $6.65 to $6.87.
• After these transactions, Adam Dubow directly beneficially owns 54,858 shares of common stock and 104,695 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving RSU vesting and a subsequent sale to cover tax liabilities, which is a neutral event and does not indicate a change in company fundamentals or management's confidence beyond standard compensation practices.

Positives

• Management's continued equity ownership aligns interests with shareholders.
• The sale was for tax purposes, indicating a routine transaction rather than a change in management's outlook on the company.

Negatives

• A portion of shares were sold, which slightly reduces the insider's direct equity stake.

Future Outlook

NA

Management Comments

• The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.

Industry Context

This filing is a routine insider transaction (Form 4) and does not provide specific insights into broader industry trends or competitive landscape within the biopharmaceutical sector. It reflects standard compensation practices involving equity awards.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine insider transaction for tax purposes, not indicative of a change in company performance or strategy.
• Positive for the reporting person (Adam Dubow) as it represents the realization of equity compensation.

Next Steps

• Future vesting of Restricted Stock Units (RSUs) will occur quarterly on February 15, May 15, August 15, and November 15, subject to continued service.

Key Dates

Recommendation

The filing is a standard Form 4 detailing an insider's RSU vesting and subsequent sale of shares to cover tax liabilities. This is a routine compensation event and does not provide new fundamental information about Day One Biopharmaceuticals that would warrant a change in investment recommendation. The transaction itself is neutral, reflecting standard practice rather than a shift in management's outlook or company performance.

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Liability, Adam Dubow, General Counsel, Biopharmaceuticals